Exocrine Pancreatic Insufficiency (EPI) – Pipeline Insight, 2020
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Exocrine Pancreatic Insufficiency (EPI) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Exocrine Pancreatic Insufficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Exocrine Pancreatic Insufficiency (EPI): Overview
Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. The exocrine pancreas produces three main types of enzymes: amylase, protease, and lipase. Under normal physiologic conditions, the enzymes (specifically, lipase) break undigested triglycerides into fatty acids and monoglycerides, which are then solubilized by bile salts (see Pathophysiology). Because the exocrine pancreas retains a large reserve capacity for enzyme secretion, fat digestion is not clearly impaired until lipase output decreases to below 10% of the normal level. Exocrine pancreatic insufficiency is associated with certain diseases and conditions that affect the pancreas. Chronic pancreatitis (CP) is the most common cause of Exocrine pancreatic insufficiency in adults. Over the course of years the inflammation can lead to irreversible damage to the pancreas, including the cells that secrete pancreatic digestive enzymes and the cells that produce insulin leading to diabetes.
Symptoms
The most common symptom of PEI is fatty stools (steatorrhea). Steatorrhea occurs when the digestive system is unable to absorb dietary fats. Instead, these fats pass through the intestinal tract with waste products. The stools tend to be oily, large, pale, very foul-smelling, and often float in toilet water and stay in the toilet bowl, even after flushing. Individuals with steatorrhea sometimes experience fecal incontinence or oily leakage. Intestinal gas and bloating can also occur from the fermentation of undigested food in the colon. Many individuals with PEI will experience nutritional deficiencies, especially of fat-soluble vitamins such as A, D, E, and K, since they are not taking in enough fats to help absorb these vitamins.
Diagnosis
The symptoms of PEI are often similar to other gastrointestinal illnesses, which can make diagnosis difficult. Blood tests: These can include the following:
Determination of fecal elastase and chymotrypsin (2 proteases produced by the pancreas) can be used to try to distinguish between pancreatic causes and intestinal causes of malabsorption.
Treatment
Treatment for EPI includes dietary management, lifestyle changes (i.e., decrease in alcohol consumption and smoking cessation), and pancreatic enzyme replacement therapy.
This segment of the Exocrine Pancreatic Insufficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exocrine Pancreatic Insufficiency Emerging Drugs
Further product details are provided in the report
Exocrine Pancreatic Insufficiency: Therapeutic Assessment
This segment of the report provides insights about the different Exocrine Pancreatic Insufficiency drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Exocrine Pancreatic Insufficiency: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Exocrine Pancreatic Insufficiency therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exocrine Pancreatic Insufficiency drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Exocrine Pancreatic Insufficiency (EPI) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Exocrine Pancreatic Insufficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Exocrine Pancreatic Insufficiency (EPI): Overview
Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. The exocrine pancreas produces three main types of enzymes: amylase, protease, and lipase. Under normal physiologic conditions, the enzymes (specifically, lipase) break undigested triglycerides into fatty acids and monoglycerides, which are then solubilized by bile salts (see Pathophysiology). Because the exocrine pancreas retains a large reserve capacity for enzyme secretion, fat digestion is not clearly impaired until lipase output decreases to below 10% of the normal level. Exocrine pancreatic insufficiency is associated with certain diseases and conditions that affect the pancreas. Chronic pancreatitis (CP) is the most common cause of Exocrine pancreatic insufficiency in adults. Over the course of years the inflammation can lead to irreversible damage to the pancreas, including the cells that secrete pancreatic digestive enzymes and the cells that produce insulin leading to diabetes.
Symptoms
The most common symptom of PEI is fatty stools (steatorrhea). Steatorrhea occurs when the digestive system is unable to absorb dietary fats. Instead, these fats pass through the intestinal tract with waste products. The stools tend to be oily, large, pale, very foul-smelling, and often float in toilet water and stay in the toilet bowl, even after flushing. Individuals with steatorrhea sometimes experience fecal incontinence or oily leakage. Intestinal gas and bloating can also occur from the fermentation of undigested food in the colon. Many individuals with PEI will experience nutritional deficiencies, especially of fat-soluble vitamins such as A, D, E, and K, since they are not taking in enough fats to help absorb these vitamins.
Diagnosis
The symptoms of PEI are often similar to other gastrointestinal illnesses, which can make diagnosis difficult. Blood tests: These can include the following:
- Complete blood count (CBC)
- Antigliadin and antiendomysial antibodies
Determination of fecal elastase and chymotrypsin (2 proteases produced by the pancreas) can be used to try to distinguish between pancreatic causes and intestinal causes of malabsorption.
Treatment
Treatment for EPI includes dietary management, lifestyle changes (i.e., decrease in alcohol consumption and smoking cessation), and pancreatic enzyme replacement therapy.
- Lifestyle modifications (eg, avoidance of fatty foods, limitation of alcohol intake, cessation of smoking, and consumption of a well-balanced diet)
- Vitamin supplementation (primarily the fat-soluble vitamins A, D, E, and K)
- Pancreatic enzyme replacement therapy (PERT), which is the therapeutic mainstay
This segment of the Exocrine Pancreatic Insufficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Exocrine Pancreatic Insufficiency Emerging Drugs
- MS1819: AzurRx BioPharma/Mayoly-Spindler
Further product details are provided in the report
Exocrine Pancreatic Insufficiency: Therapeutic Assessment
This segment of the report provides insights about the different Exocrine Pancreatic Insufficiency drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Exocrine Pancreatic Insufficiency
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intramuscular
- Intravenous
- Molecule Type
- Recombinant proteins
- Pancreatic enzymes
- Product Type
Exocrine Pancreatic Insufficiency: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Exocrine Pancreatic Insufficiency therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Exocrine Pancreatic Insufficiency drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Exocrine Pancreatic Insufficiency R&D. The therapies under development are focused on novel approaches to treat/improve Exocrine Pancreatic Insufficiency.
- August 2020: First patients enrolled in phase 2b trial testing MS1819 for Exocrine Pancreatic Insufficiency in CF. The OPTION 2 trial aims to evaluate the safety, tolerability, and efficacy of MS1819 compared to current standard of care, porcine (from pigs) enzyme replacement therapy. Recruitment is currently open at four U.S. locations with plans to expand to 15 locations in the U.S. and Europe.
- Exocrine Pancreatic Insufficiency Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Exocrine Pancreatic Insufficiency drugs?
- How many Exocrine Pancreatic Insufficiency drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Exocrine Pancreatic Insufficiency?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Exocrine Pancreatic Insufficiency therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Exocrine Pancreatic Insufficiency and their status?
- What are the key designations that have been granted to the emerging drugs?
- Digestive Care, Inc.
- AzurRx BioPharma, Inc.
- Abbott
- Orlando Health, Inc.
- Chiesi Farmaceutici
- Pancrelipase
- MS1819
Introduction
Executive Summary
Exocrine Pancreatic Insufficiency: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Exocrine Pancreatic Insufficiency – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Exocrine Pancreatic Insufficiency companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Exocrine Pancreatic Insufficiency Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Recombinant lipase: AzurRx BioPharma/Mayoly-Spindler
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Exocrine Pancreatic Insufficiency Key Companies
Exocrine Pancreatic Insufficiency Key Products
Exocrine Pancreatic Insufficiency- Unmet Needs
Exocrine Pancreatic Insufficiency- Market Drivers and Barriers
Exocrine Pancreatic Insufficiency- Future Perspectives and Conclusion
Exocrine Pancreatic Insufficiency Analyst Views
Exocrine Pancreatic Insufficiency Key Companies
Appendix
Executive Summary
Exocrine Pancreatic Insufficiency: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Exocrine Pancreatic Insufficiency – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Exocrine Pancreatic Insufficiency companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Exocrine Pancreatic Insufficiency Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Recombinant lipase: AzurRx BioPharma/Mayoly-Spindler
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Exocrine Pancreatic Insufficiency Key Companies
Exocrine Pancreatic Insufficiency Key Products
Exocrine Pancreatic Insufficiency- Unmet Needs
Exocrine Pancreatic Insufficiency- Market Drivers and Barriers
Exocrine Pancreatic Insufficiency- Future Perspectives and Conclusion
Exocrine Pancreatic Insufficiency Analyst Views
Exocrine Pancreatic Insufficiency Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Exocrine Pancreatic Insufficiency
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Exocrine Pancreatic Insufficiency
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Exocrine Pancreatic Insufficiency
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Exocrine Pancreatic Insufficiency
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products